I used to own shares in a company addressing unwanted fat deposits. It's addressable market was about 4 Billion. According to AVITA's website and Blackcrane's estimates AVITA has a larger TAM if we include verticals like acne scarring and vitiligo;maybe as much as 4 times the TAM of ZLTQ. ZLTQ was purchased by AGN for 2.47B or $56.69/share. At the time of the purchase ZLTQ's it had a sales run rate of 350M. AGN paid about 7 times sales; but given AVITA's larger TAM she could command more. I see ZLTQ as an analog to AVITA. All it has to do is execute. We know the device/technology works. AGN has a strong aesthetics business so may eventually be interested. Just brainstorming.
News 
Market Data 
Discover 
AI
